Clinical Trial Update: A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. [Phase 2]

View source ↗

Summary

An update on an ongoing Phase 2 trial studying selinexor with low-dose dexamethasone in penta-refractory multiple myeloma, and selinexor with bortezomib plus lo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Selinexor (selinexor)

Snippet

Sponsor: Karyopharm Therapeutics Inc | Conditions: Multiple Myeloma, Refractory | Phase 2 | Status: RECRUITING